Hyperfine (HYPR) and The Competition Financial Contrast

Hyperfine (NASDAQ:HYPR) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Hyperfine to related businesses based on the strength of its profitability, analyst recommendations, earnings, risk, valuation, institutional ownership and dividends.

Institutional and Insider Ownership

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Hyperfine and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	1	3	1	2.67
Hyperfine Competitors	4290	10574	18359	830	2.46

Hyperfine currently has a consensus target price of $2.02, indicating a potential upside of 184.69%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.54%. Given Hyperfine’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Hyperfine is more favorable than its competitors.

Volatility & Risk

Hyperfine has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Hyperfine’s competitors have a beta of 2.57, meaning that their average share price is 157% more volatile than the S&P 500.

Earnings & Valuation

This table compares Hyperfine and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hyperfine	$11.40 million	-$35.57 million	-1.87
Hyperfine Competitors	$1.89 billion	$136.81 million	5.75

Hyperfine’s competitors have higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Hyperfine and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-156.42%	-91.18%	-55.49%
Hyperfine Competitors	-304.20%	-315.07%	-22.11%

Summary

Hyperfine competitors beat Hyperfine on 7 of the 13 factors compared.

Hyperfine Company Profile

Hyperfine, Inc. (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings. Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside. The system is designed to produce brain images without requiring patients to be transported to a traditional radiology department.